The positivity rate of FSCN1 protein in tumor stage II–IV group (23.3%, 7/30) was higher than in stage I patients (10.2%, 8/78), but the difference was also not statistically significant (P = 0.147). This evidence concerns the gene FSCN1 and neoplasm.